Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 8,12 € (+666,04 %). Medianen er 8,12 € (+666,04 %).

Køb	13
Behold	2
Sælg	1

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

Nyheder Til nyhedsfeedet

InflaRx shifts strategy toward kidney diseases and backs oral izicopan

InflaRx is shifting its focus from immunodermatology to complement-mediated kidney diseases and is positioning oral izicopan as its lead program, particularly for ANCA-associated vasculitis (AAV). The company plans a Phase IIb study in AAV for early 2025, is in talks with the FDA about efficacy endpoints, and sees market opportunities after the withdrawal of TAVNEOS in Europe. InflaRx reports financing through 2029 following a $150 million round, but continues to cite risks such as reaching agreement with the FDA, manufacturing preparations, and potential additional capital needs for later stages. » Mere på de.investing.com
InflaRx focuses on kidney diseases with INF904 as lead candidate

InflaRx is shifting its focus to ANCA-associated vasculitis and other kidney diseases and sees a larger market opportunity due to safety issues with avacopan. INF904 is presented as an orally available C5aR1 inhibitor with improved pharmacokinetics and a favorable liver safety profile compared with avacopan. Vilobelimab remains planned as a second, more rapidly available option for remission induction. The company is in discussions with the FDA about study design and endpoints and plans a phase II study with INF904; clinical and regulatory hurdles remain. » Mere på de.investing.com
InflaRx examines EMA approval pathways for AAV drugs Vilobelimab and Izicopan

InflaRx has opened talks with the EMA on possible approval routes in Europe for the anti‑C5a antibody Vilobelimab and the oral C5aR inhibitor Izicopan to treat ANCA‑associated vasculitis (AAV). The review follows the CHMP recommendation to withdraw the approval of Tavneos and aims to clarify the most efficient development path to make C5a/C5aR inhibitors available to patients. InflaRx describes Vilobelimab as phase‑3 ready after completion of two phase‑2 trials; phase‑2 planning for Izicopan will continue regionally. According to InvestingPro the stock has recently risen sharply, but the company reports a solid liquidity position with more cash than debt. » Mere på de.investing.com
InflaRx closes $150 million placement

InflaRx placed 75,000,000 common shares at $2.00 each, generating gross proceeds of $150 million before fees. The company said it will use the net proceeds to advance its product pipeline, for working capital and for general corporate purposes; new and existing institutional investors participated in the offering. According to InvestingPro, InflaRx is currently overvalued relative to its fair-value estimate and had negative free cash flow of $41.6 million over the past twelve months. » Mere på de.investing.com
InflaRx plans izicopan development for AAV and secures funding

InflaRx announces phase‑2 planning for the oral C5a receptor inhibitor izicopan in ANCA‑associated vasculitis (AAV) and is exploring accelerated development pathways. The company aims to generate proof‑of‑concept data for izicopan in additional complement‑mediated kidney diseases (aHUS, IgAN, C3G) in open‑label studies; initial clinical data are expected in 2027. Plans include a pharmacokinetic bridging study in China later this year, a capital‑markets day in summer 2026 and a webcast on May 8 to discuss strategy. InflaRx is pursuing a guaranteed capital increase of 75 million common shares at $2.00 each, with closing expected on May 7; proceeds are intended to fund programs to key milestones and operations through 2029. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde InflaRx en omsætning på 0 € og et nettoresultat på -2,44 mio. €

(EUR)	september 2026	YoY
Omsætning	0	100,00 %
Bruttofortjeneste	-85,14 t	462,33 %
Nettoresultat	-2,44 mio.	80,10 %
EBITDA	-2,34 mio.	80,71 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	173,43 mio. €
Antal aktier	147,37 mio.
Højeste/laveste i 52 uger	2,66 € - 0,72 €
Udbytte	Nej
Beta	2,40
P/E (PE Ratio)	-3,59
PEG (PEG Ratio)	-0,06
K/I (PB Ratio)	1,19
P/S (PS Ratio)	-5.065,34

Virksomhedsprofil

InflaRx N.V., et klinisk fase biofarmaceutisk selskab, opdager og udvikler hæmmere ved hjælp af C5a-teknologi, primært i Tyskland og USA. Selskabets C5a er en inflammatorisk mediator, som er involveret i udviklingen af en række autoimmune og andre inflammatoriske sygdomme. Dets vigtigste produktkandidat er vilobelimab, en ny, intravenøst administreret, first-in-class anti-C5a monoklonal antistof, som har gennemført fase III-forsøget til behandling af hidradenitis suppurativa, en sjælden og kronisk invaliderende systemisk inflammatorisk hudsygdom; til behandling af anti-neutrofil cytoplasmatisk antistofassocieret vaskulitis, en sjælden og livstruende autoimmun sygdom, som er i fase II-forsøg; til behandling af pyoderma gangrenosum, en kronisk inflammatorisk hudlidelse, som er i et eksplorativt fase IIa-studie; og til behandling af PD-1/PD-L1-hæmmerresistent/refraktær lokalt avanceret eller metastatisk cutant pladecellekarcinom, som er i den kliniske udviklingsfase II. Selskabet udvikler også INF904, en oral, småmolekylær lægemiddelkandidat til ikke-oplyste kroniske inflammatoriske og autoimmune sygdomme; samt IFX002, som er i præklinisk udviklingsfase til behandling af kronisk inflammation og autoimmune sygdomme. Selskabet har en co-udviklingsaftale med Beijing Defengrei Biotechnology Co. Ltd. og en klinisk forsøgssamarbejds- og leveranceaftale med Merck & Co. Inc. Selskabet var tidligere kendt som Fireman B.V. og skiftede navn til InflaRx N.V. i 2017. InflaRx N.V. blev grundlagt i 2007 og har hovedkvarter i Jena, Tyskland.